as 01-17-2025 4:00pm EST
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Founded: | 1981 | Country: | Canada |
Employees: | N/A | City: | VANCOUVER |
Market Cap: | 3.4M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 26.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -13.79 | EPS Growth: | N/A |
52 Week Low/High: | $2.42 - $15.70 | Next Earning Date: | 02-11-2025 |
Revenue: | $4,960,506 | Revenue Growth: | 5.17% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
INM Breaking Stock News: Dive into INM Ticker-Specific Updates for Smart Investing
Newsfile
a month ago
Newsfile
a month ago
Newsfile
2 months ago
Newsfile
2 months ago
Newsfile
2 months ago
Newsfile
2 months ago
Newsfile
3 months ago
Newsfile
3 months ago
The information presented on this page, "INM InMed Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.